Anaeropharma has presented new research outcomes at AACR Conference on Tumor Immunology and Immunotherapy

At AACR Special Conference on Tumor Immunology and Immunotherapy took place October 1-4, 2017 in Boston, MA, Anaeropharma has presented its new research outcomes regarding cancer immunotherapy titled “Anti-PD-1 antibody scFv producing recombinant Bifidobacterium exerts antitumor effect in a larger fraction of the treated mice comparing to full length anti-PD-1 antibody”.

PDF download here

 

Comments are closed.